Suvorexant (Belsomra ® ) is a relatively new insomnia medication that has been available in the USA and Japan since 2014. It is a dual orexin receptor antagonist that promotes sleep by inhibiting the binding of orexin neurons to the OX1R and OX2R receptors. In this report, we describe the detection and quantitation of suvorexant from the postmortem specimens of three separate autopsy cases handled by our department. Suvorexant was identified by fast gas chromatography/mass spectrometry during routine screening, and quantitated by a fully validated liquid chromatography-tandem mass spectrometry method. Quantitation was achieved by positive electrospray ionization in the selected reaction monitoring mode. Monitored transitions were m/z 451 > 186 for quantitation and m/z 451 > 104 for qualification. To our knowledge, this is the first instance of suvorexant being quantitated from actual autopsy cases. It is likely that this compound will be encountered more often by the forensic toxicology community going forward.
Introduction
Suvorexant, also known by its trade name Belsomra  , is a relatively new sedative hypnotic distributed by Merck & Co. for the treatment of insomnia (1) . Suvorexant was approved for use by the U.S. Food & Drug Administration in 2014 and released in the United States and Japan in August and November of that year, respectively (2, 3) .
Suvorexant is used to treat insomnia in patients by regulating the sleep-wake cycle. It is similar in usage to other insomnia medication like zolpidem (Ambien  ), eszopiclone (Lunesta  ) and zaleplon (Sonata  ); however, its mechanism of action is quite different.
Suvorexant promotes sleep through the binding inhibition of orexin A (hypocretin-1) and orexin B (hypocretin-2), neuropeptides that promote wakefulness (4). It accomplishes this
by blocking the ability of these neurons to bind to the orexin-1 (OX1R) and orexin-2 (OX2R) receptors, effectively inhibiting the activation of arousal or wakefulness (5) . The chemical structure, chemical formula, and molecular weight of suvorexant can be seen in Suvorexant is prescribed in oral doses of between 5 and 20 mg. The onset of sleep typically occurs between 56 to 68 minutes after oral ingestion. Reported side-effects include somnolence, muscle weakness, abnormal dreams, and headache. Its oral bioavailability is 82% and peak plasma concentrations typically occur between 2 and 3 h after administration. Its mean volume of distribution (Vd) has been reported as between 49 and 105.9 L, it is 99% bound to plasma proteins, and its reported half-life (t½) is 12 hours (6) . Metabolism is primarily performed by cytochrome P450 (CYP3A4), and over To our knowledge, there have been no published reports involving suvorexant detected from human postmortem samples. Several reports regarding the analysis of suvorexant in spiked samples, human clinical studies and animal studies have been published. Analysis of suvorexant has been accomplished by gas chromatography/mass spectrometry (GC-MS), high-performance liquid chromatography-tandem mass spectroscopy (HPLC-MS/MS), ultra-performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS), and liquid chromatography-quadrupole/time-of-flight mass spectrometry (LC-Q/TOF-MS) (8) (9) (10) (11) .
In this study, we describe the identification of suvorexant by GC-MS(/MS) and LC-MS-MS, the validation of an LC-MS-MS quantitation method for suvorexant, and the tissue distribution in postmortem specimens from three autopsy cases.
Materials and Methods

Chemicals and reagents
Suvorexant, as a solid powder in its free form, was purchased from MedChem Express (Monmouth Junction, New Jersey, USA). A methanolic solution (1 mg/mL) of diazepamd5 was purchased from Cerilliant Corporation (Round Rock, Texas, USA) for use as the internal standard (IS). Acetonitrile and methanol, both HPLC-grade, were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Formic acid and n-propyl acetate were acquired from Kanto Chemical Co., Inc. (Tokyo, Japan). Solid tissues were homogenized using a µT-12 beads crusher (TAITEC, Saitama, Japan). Captiva Non-Drip (ND) Lipids filtration cartridges (3 mL) were purchased from Agilent (Santa Clara, CA, USA). Water was distilled using an Aquarius Automatic Water Distillation Apparatus (RFD230CA, Advantec, Ehime, Japan). Blank human whole blood was purchased from Biopredic International (Rennes, France). Blank urine was provided by a volunteer and tested prior to use to ensure the absence of interfering compounds.
Preparation of calibration samples
A stock solution of 1 mg/mL of suvorexant was prepared by weighing out solid powder and dissolving in a solution of acetonitrile:distilled water (1:1). The stock solution was serially diluted in acetonitrile to prepare working stock solutions. Blood and urine calibrators were prepared by spiking 10 L of the appropriate working standard into 200 L of blank sample for final concentrations of 1, 5, 10, 25, 50, 100, 250, and 500 ng/mL.
Tissue specimens were quantitated by using the standard addition method, by directly spiking into 0.2 g of homogenized case sample tissue for final concentrations of 0, 25, 50, 100, 250, and 500 ng/mL. A working IS solution was prepared by dilution of the 1 mg/mL stock solution with methanol to a concentration of 2,000 ng/mL.
Preparation of case samples
Whole blood, urine, and tissue specimens collected at autopsy were kept frozen at -30C until analysis. The preparation method for postmortem body fluid samples for the routine screening of drugs by fast GC-MS can be found in a previous report (12) . 
GC-MS equipment and conditions
The GC-MS system was a GCMS-TQ8030 (Shimadzu, Kyoto, Japan). The column used Table I .
The LC system was a Prominence liquid chromatograph (Shimadzu, Kyoto, Japan) with a binary pump and integrated degasser, autosampler, and heated column compartment.
The detection system was a TSQ Quantum Access MAX tandem mass spectrometer To determine the appropriate transitions to monitor for detection in the selected reaction monitoring (SRM) mode, a shooting standard of suvorexant at a concentration of 1 g/mL in mobile phase was infused into the MS/MS for determination of the optimal precursor and product ions and their respective collision energies. The optimum transitions and collision energies for suvorexant can be found in Table I . The SRM transitions determined by this method were consistent with the MS/MS conditions reported by publications referenced in this article (9-11).
Method validation
The LC-MS-MS quantitation method used in this report was validated with recommended guidelines (14) . Bias and precision were assessed by the analysis of quality control (QC) samples in blank whole blood and blank urine prepared at concentrations of 3, 100, and 400 ng/mL measured in triplicate over five different runs. Acceptable results were bias and precision (coefficient of variation, CV) within ±20%. The calibration model was evaluated by the least-squares linear regression method over five different runs. Carryover was assessed by analyzing blank matrix extracts following the injection of the highest calibration level (500 ng/mL). Endogenous matrix interference was evaluated by extracting 10 different whole blood and urine sources that were negative for suvorexant and the IS. To evaluate interferences from other commonly encountered analytes, blank whole blood and urine samples were spiked with 20 commonly encountered drugs ( phase were spiked at the same concentrations. Matrix effect (ME) was assessed by comparing the peak area ratios (analyte/IS) for the extracted whole blood/urine and the spiked mobile phase. Acceptable results were ME and CV values of less than 25% and 15%, respectively. Extraction recovery was measured by comparing the peak areas of suvorexant from samples extracted from spiked whole blood/urine to non-extracted samples at 100 ng/mL. Limit of detection (LOD) and limit of quantitation (LOQ) were determined by analyzing suvorexant spiked into three blank whole blood and urine samples from different sources at decreasing concentrations processed in three separate analyses. The LOD was determined to be the lowest concentration that produced a peak with a signal to noise ratio of greater than 3:1 at the expected retention time. The LOQ was determined to be the lowest concentration that produced a peak with a signal to noise ratio of at least 10:1 at the expected retention time and was within ±20% of the spiked concentration. Stability was measured by reanalyzing the QC samples after storage at 4°C at 6, 12, 18, and 24 h.
Application to Actual Autopsy Cases
Between October of 2016 and August of 2017, the Department of Forensic Medicine at Fukuoka University encountered three autopsy cases involving suvorexant.
Case 1
A female in her early forties was found washed up on a beach. She had a history of depression and was prescribed several medications, including Belsomra  . An autopsy was conducted soon after her body was discovered. Autopsy findings revealed that water and white foam were present in the airway and the lungs displayed oedema aquosum.
There were no other remarkable wounds found on the body. Diatoms found in the lungs, liver, and kidneys were consistent with diatoms from the water near where she was found.
Toxicology results revealed the presence of several prescription medications in the blood.
The medications, excluding suvorexant, and their concentrations in cardiac blood can be found in Table II . Olanzapine, quetiapine, 7-aminoflunitrazepam and flunitrazepam were detected. Ethanol in the blood was negative. The cause of death was determined to be drowning.
Case 2
A male in his mid-50s was found dead lying prone in his bedroom. He had many pharmaceutical prescriptions, including Belsomra  . The decedent was autopsied soon after his death was discovered. Autopsy findings revealed no remarkable wounds, however the oral cavity, esophagus, tracheobronchi and stomach all contained a bluishgreen substance. Rohypnol  , a benzodiazepine hypnotic used to treat insomnia and infamous for its intense blue-green color once dissolved, was among the medications prescribed to the deceased. Ethanol was not detected, but toxicology testing revealed many drugs present in the blood and urine. The 15 other drugs, excluding suvorexant, and their concentrations in cardiac blood can be found in Table II . Toxic levels of promethazine and elevated levels of nifedipine, chlorpromazine and zotepine were detected in the blood and urine. Due to the number of medications, some of which were at toxic or elevated levels, and a lack of other relevant autopsy findings, the cause of death was determined to be combined drug intoxication.
Case 3
A male in his 80s was discovered by his son who came home and found him incompletely suspended by his neck from an extension cord in a workroom. The deceased had become blind from diabetes ~10 years ago. He had a history of acute myocardial infarction 25 years ago. At the time of death, he had been visiting the hospital regularly for diabetes and anxiety. Belsomra  , triazolam and other medications were prescribed. An autopsy was performed less than 24 h of the discovery of the body. Autopsy revealed a deep, distinct furrow encircling the neck with subcutaneous bleeding and a fracture of the upper left corner of the thyroid cartilage. Ethanol in the blood was 0.02 mg/mL. The concentrations in cardiac blood of the other drugs found in his system are shown in Table   II . The manner and cause of death was suicide by hanging.
Results and Discussion
Results of GC-MS(/MS) screening
The chromatogram and spectra from the fast GC-MS screening of suvorexant from the right heart blood of Case 1 can be seen in Figures 2 and 3 , respectively. The low concentration of suvorexant in Case 2 made screening in the scan mode difficult, so an MRM mode method was developed to improve the sensitivity (Figure 4 ). In the fast GC-MS analysis utilized by our department, the retention time for suvorexant was 5.25 min.
Suvorexant has a high boiling point (669C) and is highly retained using gas chromatography (11) . To demonstrate the high degree of retention, a shooting standard of suvorexant (10 g/mL) was analyzed using conditions that are commonly used for GC-MS screening. The resulting chromatogram can be seen in Figure 5 . With a retention time of 23.7 min, this compound could easily be missed if data acquisition were not long enough or if the analyst did not know to search for it.
Results of the LC-MS-MS method validation
The LC-MS-MS product ion spectrum and chromatogram for suvorexant can be seen in Figures 6 and 7 , respectively. A summary of the bias and precision of the quantitative method can be seen in Table III . The within-run CVs for blood and urine were 3-16% and 2-15%, respectively. The between-run CVs for blood and urine were 3-12% and 3-15%, respectively. Linear calibration curves were constructed using spiked blank whole blood or urine, or standard addition by spiking directly into the tissue homogenates. The average coefficient of determination (R 2 ) for the blood and urine curves were 0.995 and 0.997, respectively. The R 2 for the standard addition curves were >0.992 (0.992-0.996).
Carryover was not observed following the highest calibrator containing 500 ng/mL of suvorexant. Post-extraction addition for whole blood and urine was used to determine ME.
For whole blood, the mean ME was -13 and -12% at 20 and 200 ng/mL, respectively. The CV in whole blood was 5 and 3% at 20 and 200 ng/mL, respectively. For urine, the mean ME was -17 and -11% at 20 and 200 ng/mL, respectively. The CV in urine was 13 and 5% at 20 and 200 ng/mL, respectively. The average extraction recovery in whole blood and urine over 5 separate analyses at 100 ng/mL was 83 ± 7% and 92 ± 6%, respectively.
These are comparable to other recent publications (9-11). There were no interferences observed from either blank matrix or from 20 commonly detected analytes spiked into either matrix. LOD was 0.5 ng/mL in both whole blood and urine. LOQ was 1 ng/mL for both whole blood and urine. Stability at 4°C was confirmed after 6, 12, 18 and 24 h (92-99%).
Quantitation results
The concentrations of suvorexant in the body fluids and tissues from all cases can be seen in Table IV . The concentration of suvorexant in the blood sources from Case 1 (421-491 ng/mL) suggested a level higher than the peak plasma levels reported from the recommended 10 or 20 mg oral dose (15) (16) (17) (18) . Sun et al. (16) studied the pharmacokinetics of suvorexant in healthy young men and reported that an oral dose of 50 mg resulted in an average peak plasma concentration of 392 ng/mL (range: 275-559 ng/mL). Based on police records, the decedent in Case 1 was prescribed 20 mg tablets of Belsomra  , with instructions to take one tablet before bedtime in cases of insomnia.
The decedent in Case 2 was also prescribed 20 mg tablets of Belsomra  to be taken once nightly. The suvorexant levels in the blood from Case 2 (11-17 ng/mL) were well below the reported peak plasma levels in any of the clinical studies that have been published. The concentration of suvorexant in the specimens of this case were much lower than in Case 1 (Table IV) . A total of 16 drugs were found in the decedent's postmortem blood, some at toxic levels, and thus the death was reported as combined drug intoxication.
The decedent in Case 3 also had a prescription for 20 mg tablets of Belsomra  to be taken once nightly. The concentration of suvorexant in the blood of this case (138-155 ng/mL) were in between those of Cases 1 and 2 (Table IV) . The cause of death in this case was determined to be hanging.
Discussion of tissue distribution
To our knowledge this is the first report of suvorexant being found in postmortem samples.
There are many factors that influence the discussion of postmortem toxicology findings in comparison to clinical studies. Interpretation of postmortem drug levels are often subject to postmortem artifacts, postmortem redistribution (PMR), pharmacogenomics and other factors (19). Thus, it is difficult to speculate on the amount of suvorexant consumed in these cases, and the effect on the deceased. More studies on suvorexant in postmortem samples are needed.
The distribution of suvorexant in the specimens of the three cases can be found in Table IV . Case 1 exhibited the highest levels of suvorexant, with the highest concentrations in the blood samples, followed by the fat, kidney and liver. Case 3 showed the highest level of suvorexant in the fat, followed by the kidney, liver, femoral vein blood and cardiac blood. Case 2 displayed the lowest concentration overall, with the highest level found in the lung, followed by the left heart blood, right heart blood, and femoral blood. While it is difficult to identify any significant pattern, it appears the drug readily accumulates in the blood, fat, kidney and liver. Blood/plasma (b/p) ratios have yet to be experimentally examined in humans, but with such high plasma protein binding (99%), it is reasonable to assume the b/p ratio would be around 0.5 or so (20). Plasma is often difficult to extract from postmortem whole blood, which was the case with these samples.
Suvorexant does not appear to exhibit marked PMR; central/peripheral (C/P) ratios ranged from 0.89 to 1.36 in these three cases. The Vd of suvorexant has been reported in several of the sources referenced in this publication, but some of them seem to disagree. what we saw in these cases, particularly with Case 1, where the highest levels were in the blood sources, and the C/P levels were close (right heart blood to femoral blood, 1.08).
In Case 2, the highest levels were in the fat, kidney, and liver, followed by the blood Tables   Table I. Chromatographic separation and mass spectrometry conditions for suvorexant 
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